0001193125-21-262692.txt : 20210901 0001193125-21-262692.hdr.sgml : 20210901 20210901083100 ACCESSION NUMBER: 0001193125-21-262692 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20210826 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20210901 DATE AS OF CHANGE: 20210901 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Avidity Biosciences, Inc. CENTRAL INDEX KEY: 0001599901 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 461336960 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39321 FILM NUMBER: 211228870 BUSINESS ADDRESS: STREET 1: 10975 N. TORREY PINES RD., STREET 2: #150 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 858-401-7900 MAIL ADDRESS: STREET 1: 10975 N. TORREY PINES RD., STREET 2: #150 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: Avidity Biosciences LLC DATE OF NAME CHANGE: 20161227 FORMER COMPANY: FORMER CONFORMED NAME: Avidity NanoMedicines LLC DATE OF NAME CHANGE: 20140211 8-K 1 d215270d8k.htm 8-K 8-K
false 0001599901 0001599901 2021-08-26 2021-08-26

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 26, 2021

 

 

AVIDITY BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39321   46-1336960

(State or other jurisdiction of

incorporation or organization)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

10975 N. Torrey Pines Road, Suite 150

La Jolla, California 92037

(Address of principal executive offices) (Zip Code)

(858) 401-7900

(Registrant’s telephone number, include area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share   RNA   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 26, 2021, Jae B. Kim, M.D. informed Avidity Biosciences, Inc. (the “Company”) of his intention to resign as Chief Medical Officer of the Company, effective August 30, 2021, for personal reasons. In connection with his resignation, the Company entered into a separation agreement with Dr. Kim, pursuant to which Dr. Kim, in exchange for a general release of claims and his agreement to various other customary restrictive covenants, will be eligible to receive certain severance benefits. The foregoing description of the separation agreement does not purport to be complete and is qualified in its entirety by reference to the separation agreement, which will be filed as an exhibit 10.1 to the Company’s Form 10-Q to be filed for the quarter ending September 30, 2021, and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    AVIDITY BIOSCIENCES, INC.
Date: September 1, 2021     By:  

/s/ Michael F. MacLean

      Michael F. MacLean
      Chief Financial Officer
 EX-101.SCH 2 rna-20210826.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 rna-20210826_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 rna-20210826_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 d215270d8k_htm.xml IDEA: XBRL DOCUMENT 0001599901 2021-08-26 2021-08-26 false 0001599901 8-K 2021-08-26 AVIDITY BIOSCIENCES, INC. DE 001-39321 46-1336960 10975 N. Torrey Pines Road Suite 150 La Jolla CA 92037 (858) 401-7900 false false false false Common Stock, par value $0.0001 per share RNA NASDAQ true false XML 6 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Aug. 26, 2021
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001599901
Document Type 8-K
Document Period End Date Aug. 26, 2021
Entity Registrant Name AVIDITY BIOSCIENCES, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-39321
Entity Tax Identification Number 46-1336960
Entity Address, Address Line One 10975 N. Torrey Pines Road
Entity Address, Address Line Two Suite 150
Entity Address, City or Town La Jolla
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92037
City Area Code (858)
Local Phone Number 401-7900
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol RNA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d215270d8k.htm rna-20210826.xsd rna-20210826_lab.xml rna-20210826_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d215270d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d215270d8k.htm" ] }, "labelLink": { "local": [ "rna-20210826_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "rna-20210826_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "rna-20210826.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "rna", "nsuri": "http://www.aviditybiosciences.com/20210826", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d215270d8k.htm", "contextRef": "duration_2021-08-26_to_2021-08-26", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d215270d8k.htm", "contextRef": "duration_2021-08-26_to_2021-08-26", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.aviditybiosciences.com//20210826/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 13 0001193125-21-262692-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-262692-xbrl.zip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